Maintenance Notice (12:30 AM - 5:30 AM August 24, 2025): This website is scheduled to be unavailable due to maintenance. We appreciate your patience and understanding.
Published TCIMAIL newest issue No.198
Maximum quantity allowed is 999
Since the first report published by Miyasaka et al. in 2009,1) research and development of metal halide perovskite solar cells (PSCs) have been carried out as a solar cell that can achieve high performance using solution process, and the power conversion efficiency (PCE) of the solar cells has reached 26%.2) Leading research institutes and industries that promote solar cell research try to upscaling and modularization of practical PSCs. However, many challenges such as improving the stability of the devices still remain in commercializing PSCs. In order to solve the problem, development of new hole transport materials and optimizing the composition of perovskite layers are mainly conducted.
The widely used hole transport materials (HTMs), Spiro-OMeTAD and PTAA, are too expensive for the production of low cost PSCs. Also, some additives such as lithium salts and cobalt complexes, which cause deceasing of device stability, have to be used to enhance PCE of devices.
TCI has developed new HTMs TOP-HTM-α1 (Product No. B5672) and TOP-HTM-α2 (Product No. T3722). These HTMs are available at reasonable prices. MAPbI3-based PSCs based on TOP-HTM-α1 and TOP-HTM-α2 exhibit significant PCEs both with and without additives, and these devices also show superior device stability than device based on Spiro-OMeTAD (Application 1).3) In addition, PSCs based on TOP-HTM-α2 could exhibit higher PCE and superior device stability by composition engineering of perovskite layer from MAPbI3 to FAPbI3 (Application 2).4) Furthermore, TOP-HTM-α2 with additives shows superior PCE with improvement of hole transport layer (HTL) morphology by selection of solvent (Application 3).5)
†These data are from reference 3.
†These data are from reference 4.
†These data are from reference 5.
HTMs are dissolved in solvents at concentration of 40 mg/mL.
*For more details, see the following reference 3 and 4.